Evidence map›Paper›PMID 42209458›Full record

ArticleCell death & disease2026

Efficacy of dual KRAS

Simonetta M Leto, Francesco Sassi, Eugenia R Zanella, Valentina Vurchio, Francesca Cottino, Martina Ferri, Antonella Damico, Elena Grassi, Andrea Bertotti, Livio Trusolino

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Simonetta M LetoCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy.ORCID http://orcid.org/0000-0001-7580-6584
Francesco SassiCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy.
Eugenia R ZanellaCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy.
Valentina VurchioCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy.
Francesca CottinoCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy.
Martina FerriCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy.
Antonella DamicoCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy.
Elena GrassiCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy.ORCID http://orcid.org/0000-0003-1066-927X
Andrea BertottiCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy. andrea.bertotti@ircc.it.ORCID http://orcid.org/0000-0001-8196-7608
Livio TrusolinoCandiolo Cancer Institute-FPO IRCCS, 10060, Candiolo, Torino, Italy. livio.trusolino@ircc.it.ORCID http://orcid.org/0000-0002-6379-3365

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 5x1000 21091Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) Accelerator 22795Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 20697Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 30315EC | EU Framework Programme for Research and Innovation H2020 | H2020 Excellent Science (H2020 Priority Excellent Science) 754923 COLOSSUSEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ERC Consolidator Grant 724748 BEATEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Research Infrastructures (H2020 Excellent Science - Research Infrastructures) 731105 EDIReXMinistry of Education, University and Research | Instituto Nazionale di Fisica Nucleare (Italian Institute for Nuclear Physics) National Recovery and Resilience Plan (PNRR), project PNC0000001Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute (Italian Medicines Agency) Ricerca Corrente 2025Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute (Italian Medicines Agency) Ricerca Finalizzata 2021 Giovani Ricercatori, ID GR-2021-12375316Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute (Italian Medicines Agency) Ricerca Finalizzata 2021, ID RF-2021-12372851Regione Piemonte (Region of Piedmont) FESR 2021-2027, grant SWIch, project IPeR
6 · The paper itself

Abstract

KRAS

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsMutationProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorCetuximabErbB ReceptorsFemaleHumansMiceProtein Kinase InhibitorsPyridonesPyrimidinonesSignal TransductionThiazolesAlpelisibCetuximabEGFR protein, humanErbB ReceptorsKRAS protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)PyridonesPyrimidinonesThiazolestrametinib

Identifiers

PMID42209458
PMCPMC13402710

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.